Drug Trial Radar · NCT04676373
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen
Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Mar 10, 2021
Primary completion
Jul 25, 2024
Study completion Jul 25, 2024
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the effect of one-year Alglucosidase alfa treatment on motor function \[Six-minute walk test (6MWT) and lung function predicted Forced vital capacity (FVC)\] among Chinese Late Onset Pompe Disease patients above 5 years old. To evaluate the safety of Myozyme 20mg/kg, IV biweekly in Chinese LOPD patients above 3 years old. Secondary Objective: To evaluate the effect of one-year treatment with Alglucosidase alfa on improvement of manual muscle test (MMT), Maximal inspiratory and expiratory pressure (MIP and MEP)\], Quick Motor Function Test scores, and health-related quality of life (SF-12) among LOPD patients over 5 years old.
Conditions
- Pompe's Disease
Interventions
ALGLUCOSIDASE ALFADrug
Pharmaceutical form:solution for infusion Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Six-minute walk test (6MWT) for the patients ≥5-year oldTime frame: Baseline to 12 months
- Change from baseline in percent predicted forced vital capacity (%FVC) in upright position for the patients ≥5-year oldTime frame: Baseline to 12 months
- Number of participants with adverse events Number of AEsTime frame: From signing the ICF to the 30th day after the last dosage of the study medications
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site
China, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.